TY - JOUR
T1 - Salt Disproportionation in the Solid State
T2 - Role of Solubility and Counterion Volatility
AU - Thakral, Naveen K.
AU - Behme, Robert J.
AU - Aburub, Aktham
AU - Peterson, Jeffrey A.
AU - Woods, Timothy A.
AU - Diseroad, Benjamin A.
AU - Suryanarayanan, Raj
AU - Stephenson, Gregory A.
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/12/5
Y1 - 2016/12/5
N2 - Disproportionation propensity of salts (HCl, HBr, heminapadisylate) and adipic acid cocrystal of corticotropin releasing hormone receptor-1 antagonist was studied using model free kinetics. Using thermogravimetic weight loss profile or heat flow curves from differential scanning calorimetry, an activation energy plot for salts and cocrystal was generated based on model free kinetics. This activation energy of disproportionation provided qualitative information about the solid state salt stability. To ensure the stability throughout the shelf life, “prototype” formulations of salts and cocrystal in tablet form were stored at 40 °C and several water vapor pressures. Disproportionation kinetics were studied in these prototype tablet formulations using two-dimensional X-ray diffractometry. Formulations containing the adipic acid cocrystal or heminapadisylate salt did not show disproportionation of API when stored at 40 °C/75% RH for 300 days. On the other hand, formulations containing HCl or HBr salt disproportionated. Though isostructural, the disproportionation propensity of HBr and HCl salts was quite different. The HCl salt highlighted the important role that volatility of the counterion plays in the physical stability of the formulations. Solution state stability (i.e., in dissolution medium) of salts and cocrystal was also assessed and compared with solid state stability, by determining their solubility at different pH’s, and intrinsic dissolution rate.
AB - Disproportionation propensity of salts (HCl, HBr, heminapadisylate) and adipic acid cocrystal of corticotropin releasing hormone receptor-1 antagonist was studied using model free kinetics. Using thermogravimetic weight loss profile or heat flow curves from differential scanning calorimetry, an activation energy plot for salts and cocrystal was generated based on model free kinetics. This activation energy of disproportionation provided qualitative information about the solid state salt stability. To ensure the stability throughout the shelf life, “prototype” formulations of salts and cocrystal in tablet form were stored at 40 °C and several water vapor pressures. Disproportionation kinetics were studied in these prototype tablet formulations using two-dimensional X-ray diffractometry. Formulations containing the adipic acid cocrystal or heminapadisylate salt did not show disproportionation of API when stored at 40 °C/75% RH for 300 days. On the other hand, formulations containing HCl or HBr salt disproportionated. Though isostructural, the disproportionation propensity of HBr and HCl salts was quite different. The HCl salt highlighted the important role that volatility of the counterion plays in the physical stability of the formulations. Solution state stability (i.e., in dissolution medium) of salts and cocrystal was also assessed and compared with solid state stability, by determining their solubility at different pH’s, and intrinsic dissolution rate.
KW - X-ray diffractometry
KW - cocrystal
KW - counterion
KW - disproportionation
KW - intrinsic dissolution
KW - model free kinetics
KW - salt
KW - solubility
KW - volatilization
UR - http://www.scopus.com/inward/record.url?scp=85002977549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002977549&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.6b00745
DO - 10.1021/acs.molpharmaceut.6b00745
M3 - Article
C2 - 27766882
AN - SCOPUS:85002977549
SN - 1543-8384
VL - 13
SP - 4141
EP - 4151
JO - Molecular pharmaceutics
JF - Molecular pharmaceutics
IS - 12
ER -